SCHEMBL25612824

SCHEMBL25612824

N#Cc1ccc(-c2cnc(NC(=O)c3ccc(=O)[nH]c3)s2)c2cc[nH]c12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.42
▸ KDM4E B2RXH2 3/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ POLB P06746 2/20 0.42
▸ GFER P55789 1/20 0.42
▸ APOBEC3A P31941 1/20 0.40
▸ APOBEC3G Q9HC16 1/20 0.40
▸ APOBEC3B Q9UH17 1/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ CSNK2A2 P19784 6/20 0.40
▸ CSNK2A1 P68400 6/20 0.40
▸ KDR P35968 1/20 0.37
▸ SCD O00767 1/20 0.37
▸ PDE10A Q9Y233 1/20 0.36
▸ MEN1 O00255 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ RECQL P46063 1/20 0.35
▸ CTDSP1 Q9GZU7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30481263 0.81 CSNK2A2 (0.41) MAPTKDM4EALDH1A1KMT2ARAB9A
SCHEMBL25420455 0.81 CSNK2A2 (0.41) MAPTKDM4EALDH1A1KMT2ARAB9A
SCHEMBL25612327 0.75 MKNK1 (0.54) ROCK2
SCHEMBL25612826 0.74 XDH (0.43) MAPTKDM4EALDH1A1POLBGFER
SCHEMBL25613017 0.67 CSNK2A2 (0.34) MAPTKDM4EALDH1A1POLBGFER
SCHEMBL16335425 0.61 BTK (0.73) —
SCHEMBL7284132 0.61 MLYCD (0.56) MAPTKDM4EALDH1A1POLBGFER
SCHEMBL25605163 0.60 PDE10A (0.49) MAPTKDM4EALDH1A1KMT2ARAB9A
SCHEMBL29265898 0.58 LRRK2 (0.33) —
SCHEMBL30326369 0.58 LRRK2 (0.33) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023107714-A2 METHODS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2023-06-15 — — WO disclosed
Send feedback